Neoatricon (Dopamine Hydrochloride)

Dopamine Hydrochloride, the active ingredient in Neoatricon, is an inotropic agent presented as an injection solution for intravenous use. It treats hypotension, cardiogenic shock, septic shock, acute heart failure and other low cardiac output states in hospitalized patients, helping to stabilize cardiovascular function.

GNH USA supplies Neoatricon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Neoatricon (dopamine hydrochloride) is used in cardiovascular emergencies to improve hemodynamic stability.

- Hypotension: raises blood pressure by increasing cardiac output and peripheral resistance. - Cardiogenic shock: enhances myocardial contractility and systemic perfusion. - Septic shock: supports arterial pressure when fluids and other vasopressors are insufficient. - Acute heart failure: improves cardiac output and reduces symptoms of low output. - Low cardiac output states: stabilizes hemodynamics during surgery or critical illness.

Adverse reactions may occur with intravenous dopamine administration.

Common Side Effects: - Tachycardia: increased heart rate. - Nausea or vomiting. - Headache. - Anxiety or restlessness.

Serious or Rare Side Effects: - Myocardial ischemia or infarction. - Severe hypertension or hypertensive crisis. - Tissue necrosis at the infusion site. - Life‑threatening arrhythmias requiring intervention. - Pulmonary edema. - Anaphylactic or severe allergic reactions.

When using Neoatricon, careful monitoring and specific precautions are recommended.

- Dose titration: adjust infusion rate based on real‑time blood pressure and cardiac output. - Renal function: monitor urine output and electrolytes during therapy. - Cardiac monitoring: observe for arrhythmias, ischemia, and excessive tachycardia. - Concomitant vasopressors: evaluate additive pressor effects and adjust doses accordingly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Dopamine may interact with several drug classes; awareness of major and moderate interactions helps ensure safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Beta‑blockers: may blunt the inotropic response. - Alpha‑adrenergic antagonists: reduce vasoconstrictive effect. - Calcium channel blockers: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance electrolyte shifts. - ACE inhibitors or ARBs: monitor blood pressure closely. - Anticholinergic agents: may increase tachycardia.